TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - Nasdaq
4 weeks ago • Google News
Tempest Therapeutics Inc (TPST)
US$ 7.76-3.6%
Price Chart
Key Statistics
Market Cap
$ 24.11M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
22.91K
52W High
$ 49.27
52W Low
$ 5.35
Dividend Yield
0.00%
Beta
-2.28
Technicals
50-Day MA
9.2752
200-Day MA
13.5208
52 Week High
49.27
52 Week Low
5.3495
About TPST
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers.
Employees
24
Headquarters
Brisbane, CA
CEO
Mr. Stephen R. Brady J.D., LLM
Latest News
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
4 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg